ALEXANDRIA, Va., March 5 -- United States Patent no. 12,239,615, issued on March 4, was assigned to Ketabon GmbH (Munich).
"Hydroxynorketamine for the use in the treatment of depression" was invented by Helene Rey (Pratteln, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to hydroxynorketamine for the use in the treatment of depression. In particular, the present invention concerns hydroxynorketamine for use in the treatment of depression, wherein hydroxynorketamine is administered in form of at least one prodrug, and wherein the at least one prodrug is orally administered in a modified-release dosage form."
The patent was filed on June 21, 2023, under Application No...